Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) closed at $101.02 in the last session, up 3.65% from day before closing price of $97.46. In other words, the price has increased by $3.65 from its previous closing price. On the day, 0.81 million shares were traded. RYTM stock price reached its highest trading level at $103.24 during the session, while it also had its lowest trading level at $96.7.
Ratios:
We take a closer look at RYTM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.53 and its Current Ratio is at 4.75. In the meantime, Its Debt-to-Equity ratio is 1.75 whereas as Long-Term Debt/Eq ratio is at 1.71.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on November 25, 2025, initiated with a Buy rating and assigned the stock a target price of $136.
On July 10, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $97.Goldman initiated its Buy rating on July 10, 2025, with a $97 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 11 ’25 when Cramer Pamela J. sold 3,350 shares for $111.00 per share. The transaction valued at 371,850 led to the insider holds 20,814 shares of the business.
PAMELA CRAMER bought 3,350 shares of RYTM for $350,980 on Dec 11 ’25. On Nov 20 ’25, another insider, Cramer Pamela J., who serves as the Chief Human Resources Officer of the company, sold 3,350 shares for $105.00 each. As a result, the insider received 351,750 and left with 20,814 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RYTM now has a Market Capitalization of 6741676032 and an Enterprise Value of 6585594368. For the stock, the TTM Price-to-Sale (P/S) ratio is 37.31 while its Price-to-Book (P/B) ratio in mrq is 45.27. Its current Enterprise Value per Revenue stands at 37.776 whereas that against EBITDA is -35.644.
Stock Price History:
The Beta on a monthly basis for RYTM is 2.01, which has changed by 0.8404081 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, RYTM has reached a high of $122.20, while it has fallen to a 52-week low of $45.90. The 50-Day Moving Average of the stock is -4.52%, while the 200-Day Moving Average is calculated to be 16.46%.
Shares Statistics:
According to the various share statistics, RYTM traded on average about 765.54K shares per day over the past 3-months and 676170 shares per day over the past 10 days. A total of 66.68M shares are outstanding, with a floating share count of 62.33M. Insiders hold about 6.60% of the company’s shares, while institutions hold 105.98% stake in the company. Shares short for RYTM as of 1765756800 were 5581124 with a Short Ratio of 7.29, compared to 1763078400 on 5502046. Therefore, it implies a Short% of Shares Outstanding of 5581124 and a Short% of Float of 10.71.
Earnings Estimates
. The current rating of Rhythm Pharmaceuticals Inc (RYTM) reflects the combined expertise of 11.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.76, with high estimates of -$0.36 and low estimates of -$1.03.
Analysts are recommending an EPS of between -$2.22 and -$3.34 for the fiscal current year, implying an average EPS of -$3.09. EPS for the following year is -$2.62, with 11.0 analysts recommending between -$1.13 and -$3.65.
Revenue Estimates
According to 14 analysts,. The current quarter’s revenue is expected to be $55.24M. It ranges from a high estimate of $57.5M to a low estimate of $52M. As of. The current estimate, Rhythm Pharmaceuticals Inc’s year-ago sales were $41.83MFor the next quarter, 14 analysts are estimating revenue of $58.29M. There is a high estimate of $64.8M for the next quarter, whereas the lowest estimate is $50M.
A total of 15 analysts have provided revenue estimates for RYTM’s current fiscal year. The highest revenue estimate was $192.55M, while the lowest revenue estimate was $185M, resulting in an average revenue estimate of $187.94M. In the same quarter a year ago, actual revenue was $130.13MBased on 15 analysts’ estimates, the company’s revenue will be $293.08M in the next fiscal year. The high estimate is $330.48M and the low estimate is $260.38M.
